Promising New Treatment OLN324 Shows Superior Outcomes in Eye Diseases Affecting the IRD Community
For individuals and families within the inherited retinal disease (IRD) community, news of advancements in treating vision-threatening conditions like diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) offers significant hope. These conditions, while distinct from many inherited retinal diseases, share the common devastating outcome of vision loss and often impact many in our broader community. Ollin Biosciences recently announced positive topline data from a head-to-head study of their investigational therapy, OLN324, demonstrating superior outcomes compared to an existing treatment, faricimab (Vabysmo®), in both DME and wAMD.
Ollin Biosciences reported these encouraging results from their randomized Phase 1b JADE clinical study, which compared OLN324 to faricimab (Vabysmo®) in over 160 patients with either DME or wAMD. Faricimab (Vabysmo®) is an approved treatment that targets two proteins, VEGF and Ang-2, which are involved in abnormal blood vessel growth and leakage in the eye.
Key findings from the study indicate that OLN324 demonstrated meaningfully faster and greater improvements in anatomical outcomes for patients with DME. Specifically, OLN324 led to faster and greater retinal drying in DME patients compared to faricimab. At week 12, nearly 90% of DME patients treated with a 4 mg dose of OLN324 achieved an absence of DME, defined as central subfield thickness (CST) below 325 µm, compared to 57% of patients treated with faricimab. In wAMD patients, OLN324 showed faster, greater, and more durable reductions in pigment epithelial detachment (PED) thickness compared to faricimab. The study also observed numerically greater vision gains in patients treated with OLN324 in both DME and wAMD, which were sustained through 20 weeks with fewer retreatments. Importantly, OLN324 maintained a favorable safety profile, with no cases of intraocular inflammation reported in the OLN324 arms through 20 weeks, while one case occurred in the faricimab group.
This news is particularly relevant for patients and families as it suggests a potential new treatment option that could offer improved efficacy and possibly reduce the burden of frequent injections. The ability to achieve faster and greater retinal drying and numerically better vision gains, along with favorable durability and safety, could significantly impact the quality of life for those managing these chronic conditions. OLN324 is a next-generation VEGF/Ang2 bispecific antibody, engineered for higher potency and a smaller format.
Ollin Biosciences plans to advance OLN324 into global Phase 3 clinical trials for both DME and wAMD in the second half of 2026. The company recently secured $330 million in Series B funding to support these upcoming trials. This move towards late-stage development brings the therapy closer to potentially becoming available to patients.